1. Clinical Overview
Recombinant Human Erythropoietin Alfa (rHuEPO-α) is a 165-amino acid glycoprotein produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells. It is identical in amino acid sequence to endogenous human erythropoietin but differs in glycosylation pattern. It is a hematopoietic growth factor that stimulates red blood cell production. In India, it is a critical therapy for anemia associated with chronic kidney disease (CKD) and chemotherapy, significantly reducing transfusion dependency.
| Onset | Duration | Bioavailability |
|---|---|---|
| Increased reticulocyte count is typically observed within 10 days of initiation. | The pharmacodynamic effect (rise in hemoglobin) is sustained for the duration of therapy. After discontinuation, hemoglobin levels gradually decline over several weeks. | Approximately 20-50% after subcutaneous (SC) administration; 20-30% after intravenous (IV) administration. SC route is preferred in chronic outpatient settings in India due to better bioavailability and less frequent dosing. |
2. Mechanism of Action
Erythropoietin Alfa binds to the erythropoietin receptor (EpoR) on the surface of erythroid progenitor cells in the bone marrow, primarily Colony-Forming Unit-Erythroid (CFU-E) and Burst-Forming Unit-Erythroid (BFU-E). This binding activates the JAK2/STAT5 intracellular signaling pathway, promoting cell survival, proliferation, and terminal differentiation into mature red blood cells (RBCs). It also induces the synthesis of hemoglobin.
3. Indications & Uses
- Anemia associated with Chronic Kidney Disease (CKD) in both dialysis and non-dialysis patients.
- Anemia in adult cancer patients with non-myeloid malignancies receiving myelosuppressive chemotherapy (to decrease the need for blood transfusions).
- Anemia in zidovudine-treated HIV-infected patients.
4. Dosage & Administration
Adult Dosage: CKD: Initial SC dose: 50-100 IU/kg 3 times weekly or 10,000 IU once weekly. Adjust to achieve target Hb of 10-12 g/dL (KDIGO guidelines). Cancer Chemotherapy: 150 IU/kg SC 3 times weekly or 40,000 IU SC once weekly. Adjust based on response.
Administration: For SC use: Administer in the upper arm, abdomen, or thigh. Rotate injection sites. Do not shake the vial/pre-filled syringe. Visually inspect for particulate matter or discoloration before use. The 4000IU/0.4ml strength is typically administered as a single SC injection. IV route is used primarily in hemodialysis patients, administered into the venous line at the end of dialysis.
5. Side Effects
Common side effects may include:
- Injection site pain/erythema.
- Headache.
- Hypertension (dose-dependent).
- Arthralgia.
- Pyrexia.
- Nausea.
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Heparin | Increased risk of vascular access thrombosis in dialysis patients. | Moderate |
| ACE Inhibitors (e.g., Enalapril) | May blunt erythropoietic response. | Moderate |
| Angiotensin II Receptor Blockers (ARBs) | May blunt erythropoietic response. | Moderate |
| Cyclosporine | Increased risk of seizures; monitor levels. | Moderate |
| Iron Supplements (Oral/IV) | Concomitant use is ESSENTIAL for adequate response. ESA therapy depletes iron stores. | Supplemental |
7. Patient Counselling
- DO have your blood pressure checked regularly.
- DO take iron supplements as prescribed by your doctor.
- DO learn proper SC injection technique if self-administering.
- DO rotate injection sites.
- DO keep regular appointments for blood tests (Hb, ferritin).
- DONT increase your dose or change dosing schedule without doctor's advice.
- DONT use if the solution is discolored or contains particles.
- DONT shake the vial/syringe vigorously.
8. Toxicology & Storage
Overdose: Polycythemia (Hb >14 g/dL), severe hypertension, headache, dizziness, tachycardia, flushing, thrombotic events (stroke, MI, DVT), and potentially seizures.
Storage: Store at 2°C to 8°C (in a refrigerator). Do not freeze. Protect from light. Keep in outer carton. Do not shake. For single use only - discard any unused portion. If necessary, the pre-filled syringe may be kept at room temperature (not above 25°C) for a single period of up to 7 days. Do not re-refrigerate.